Astellas Pharma (OTCMKTS:ALPMY) Stock Price Crosses Above 50 Day Moving Average – Here’s What Happened

Astellas Pharma Inc. (OTCMKTS:ALPMY) shares crossed above its 50-day moving average during trading on Tuesday . The stock has a 50-day moving average of $13.80 and traded as high as $15.17. Astellas Pharma shares last traded at $15.16, with a volume of 91,492 shares changing hands.

Wall Street Analyst Weigh In

Separately, Zacks Research lowered shares of Astellas Pharma from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, July 22nd. One equities research analyst has rated the stock with a Strong Buy rating and four have assigned a Hold rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold”.

Astellas Pharma Stock Performance

The company has a debt-to-equity ratio of 0.17, a current ratio of 1.17 and a quick ratio of 0.90. The firm has a fifty day moving average of $13.83 and a 200 day moving average of $14.68. The stock has a market cap of $27.05 billion, a price-to-earnings ratio of 11.38 and a beta of 0.08.

About Astellas Pharma

Astellas Pharma Inc is a Tokyo-based, global pharmaceutical company traded in the United States as an American Depositary Receipt on the OTC Markets under the symbol ALPMY. The company focuses on discovering, developing and marketing prescription medicines in key therapeutic areas, including oncology, urology, immunology, neuroscience and cardiovascular/metabolic diseases. Astellas seeks to bring innovative treatments to market by combining internal research capabilities with external partnerships and collaborative agreements around the world.

Core products in Astellas’ portfolio include the immunosuppressant Prograf (tacrolimus), the overactive bladder treatments Vesicare (solifenacin) and Myrbetriq (mirabegron), and the prostate cancer therapy Xtandi (enzalutamide).